Cell and Cell Free Therapies in Osteoarthritis

Osteoarthritis (OA) is the most common articular disease in adults and has a current prevalence of 12% in the population over 65 years old. This chronic disease causes damage to articular cartilage and synovial joints, causing pain and leading to a negative impact on patients’ function, decreasing q...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pau Peláez, Elena Damiá, Marta Torres-Torrillas, Deborah Chicharro, Belén Cuervo, Laura Miguel, Ayla del Romero, Jose Maria Carrillo, Joaquín J. Sopena, Mónica Rubio
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	osteoarthritis cell-based therapy cell-free therapy platelet-rich plasma mesenchymal stem cells Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/5518e813af5a436f9e2c343f06fc395b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5518e813af5a436f9e2c343f06fc395b
record_format	dspace
spelling	oai:doaj.org-article:5518e813af5a436f9e2c343f06fc395b2021-11-25T16:51:24ZCell and Cell Free Therapies in Osteoarthritis10.3390/biomedicines91117262227-9059https://doaj.org/article/5518e813af5a436f9e2c343f06fc395b2021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1726https://doaj.org/toc/2227-9059Osteoarthritis (OA) is the most common articular disease in adults and has a current prevalence of 12% in the population over 65 years old. This chronic disease causes damage to articular cartilage and synovial joints, causing pain and leading to a negative impact on patients’ function, decreasing quality of life. There are many limitations regarding OA conventional therapies—pharmacological therapy can cause gastrointestinal, renal, and cardiac adverse effects, and some of them could even be a threat to life. On the other hand, surgical options, such as microfracture, have been used for the last 20 years, but hyaline cartilage has a limited regeneration capacity. In recent years, the interest in new therapies, such as cell-based and cell-free therapies, has been considerably increasing. The purpose of this review is to describe and compare bioregenerative therapies’ efficacy for OA, with particular emphasis on the use of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP). In OA, these therapies might be an alternative and less invasive treatment than surgery, and a more effective option than conventional therapies.Pau PeláezElena DamiáMarta Torres-TorrillasDeborah ChicharroBelén CuervoLaura MiguelAyla del RomeroJose Maria CarrilloJoaquín J. SopenaMónica RubioMDPI AGarticleosteoarthritiscell-based therapycell-free therapyplatelet-rich plasmamesenchymal stem cellsBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1726, p 1726 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	osteoarthritis cell-based therapy cell-free therapy platelet-rich plasma mesenchymal stem cells Biology (General) QH301-705.5
spellingShingle	osteoarthritis cell-based therapy cell-free therapy platelet-rich plasma mesenchymal stem cells Biology (General) QH301-705.5 Pau Peláez Elena Damiá Marta Torres-Torrillas Deborah Chicharro Belén Cuervo Laura Miguel Ayla del Romero Jose Maria Carrillo Joaquín J. Sopena Mónica Rubio Cell and Cell Free Therapies in Osteoarthritis
description	Osteoarthritis (OA) is the most common articular disease in adults and has a current prevalence of 12% in the population over 65 years old. This chronic disease causes damage to articular cartilage and synovial joints, causing pain and leading to a negative impact on patients’ function, decreasing quality of life. There are many limitations regarding OA conventional therapies—pharmacological therapy can cause gastrointestinal, renal, and cardiac adverse effects, and some of them could even be a threat to life. On the other hand, surgical options, such as microfracture, have been used for the last 20 years, but hyaline cartilage has a limited regeneration capacity. In recent years, the interest in new therapies, such as cell-based and cell-free therapies, has been considerably increasing. The purpose of this review is to describe and compare bioregenerative therapies’ efficacy for OA, with particular emphasis on the use of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP). In OA, these therapies might be an alternative and less invasive treatment than surgery, and a more effective option than conventional therapies.
format	article
author	Pau Peláez Elena Damiá Marta Torres-Torrillas Deborah Chicharro Belén Cuervo Laura Miguel Ayla del Romero Jose Maria Carrillo Joaquín J. Sopena Mónica Rubio
author_facet	Pau Peláez Elena Damiá Marta Torres-Torrillas Deborah Chicharro Belén Cuervo Laura Miguel Ayla del Romero Jose Maria Carrillo Joaquín J. Sopena Mónica Rubio
author_sort	Pau Peláez
title	Cell and Cell Free Therapies in Osteoarthritis
title_short	Cell and Cell Free Therapies in Osteoarthritis
title_full	Cell and Cell Free Therapies in Osteoarthritis
title_fullStr	Cell and Cell Free Therapies in Osteoarthritis
title_full_unstemmed	Cell and Cell Free Therapies in Osteoarthritis
title_sort	cell and cell free therapies in osteoarthritis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/5518e813af5a436f9e2c343f06fc395b
work_keys_str_mv	AT paupelaez cellandcellfreetherapiesinosteoarthritis AT elenadamia cellandcellfreetherapiesinosteoarthritis AT martatorrestorrillas cellandcellfreetherapiesinosteoarthritis AT deborahchicharro cellandcellfreetherapiesinosteoarthritis AT belencuervo cellandcellfreetherapiesinosteoarthritis AT lauramiguel cellandcellfreetherapiesinosteoarthritis AT ayladelromero cellandcellfreetherapiesinosteoarthritis AT josemariacarrillo cellandcellfreetherapiesinosteoarthritis AT joaquinjsopena cellandcellfreetherapiesinosteoarthritis AT monicarubio cellandcellfreetherapiesinosteoarthritis
_version_	1718412895810748416

Cell and Cell Free Therapies in Osteoarthritis

Ejemplares similares